Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early recurrence, high invasion, and poor prognosis. Currently, its treatment includes chemotherapy, which shows a suboptimal efficacy. However, with the increasing studies on TNBC subtypes and tumor molecular biology, great progress has been made in targeted therapy for TNBC. The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. Given its importance as cancer treatment, we review the latest research on the subtypes of TNBC and relevant targeted therapies
Breast cancers are divided into at least 4 subtypes on the basis of gene expression profiles and exp...
Triple-negative breast cancers (TNBCs) are more likely to occur in younger patients and have a poor ...
The so called "Triple Negative Breast Cancer" (TNBC) represents approximately 15-20% of breast cance...
[[abstract]]Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early rec...
Triple-negative breast cancer (TNBC) is a heterogeneous disease in which tumors are defined by lack ...
Triple-negative breast cancers (TNBCs) are a diverse and heterogeneous group of tumors that by defin...
Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a he...
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive breast cancer s...
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by ...
Triple negative breast cancer (TNBC) is defined by the absence of ER, PR and normal HER-2 expression...
Triple-negative breast cancer (TNBC) accounts for approximately 15%–20% of all breast cancers. Patie...
Triple-negative breast cancer (TNBC), that is breast cancer which stains negatively at immunohistoch...
Breast cancer is the most common cancer type that affects women and is the major cause of morbidity ...
Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast cancers that hav...
Greater understanding of the biology of triple-negative breast cancer (TNBC) is needed to discern th...
Breast cancers are divided into at least 4 subtypes on the basis of gene expression profiles and exp...
Triple-negative breast cancers (TNBCs) are more likely to occur in younger patients and have a poor ...
The so called "Triple Negative Breast Cancer" (TNBC) represents approximately 15-20% of breast cance...
[[abstract]]Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early rec...
Triple-negative breast cancer (TNBC) is a heterogeneous disease in which tumors are defined by lack ...
Triple-negative breast cancers (TNBCs) are a diverse and heterogeneous group of tumors that by defin...
Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a he...
Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive breast cancer s...
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is defined by ...
Triple negative breast cancer (TNBC) is defined by the absence of ER, PR and normal HER-2 expression...
Triple-negative breast cancer (TNBC) accounts for approximately 15%–20% of all breast cancers. Patie...
Triple-negative breast cancer (TNBC), that is breast cancer which stains negatively at immunohistoch...
Breast cancer is the most common cancer type that affects women and is the major cause of morbidity ...
Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast cancers that hav...
Greater understanding of the biology of triple-negative breast cancer (TNBC) is needed to discern th...
Breast cancers are divided into at least 4 subtypes on the basis of gene expression profiles and exp...
Triple-negative breast cancers (TNBCs) are more likely to occur in younger patients and have a poor ...
The so called "Triple Negative Breast Cancer" (TNBC) represents approximately 15-20% of breast cance...